124 related articles for article (PubMed ID: 7585578)
1. p53 point mutation and survival in colorectal cancer patients.
Goh HS; Yao J; Smith DR
Cancer Res; 1995 Nov; 55(22):5217-21. PubMed ID: 7585578
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of the c-myc proto-oncogene in colorectal carcinoma is associated with a reduced mortality that is abrogated by point mutation of the p53 tumor suppressor gene.
Smith DR; Goh HS
Clin Cancer Res; 1996 Jun; 2(6):1049-53. PubMed ID: 9816266
[TBL] [Abstract][Full Text] [Related]
3. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.
Powell B; Soong R; Iacopetta B; Seshadri R; Smith DR
Clin Cancer Res; 2000 Feb; 6(2):443-51. PubMed ID: 10690522
[TBL] [Abstract][Full Text] [Related]
5. Characterization of p53 mutations in colorectal liver metastases and correlation with clinical parameters.
Tullo A; D'Erchia AM; Honda K; Mitry RR; Kelly MD; Habib NA; Saccone C; Sbisà E
Clin Cancer Res; 1999 Nov; 5(11):3523-8. PubMed ID: 10589767
[TBL] [Abstract][Full Text] [Related]
6. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival.
Lenz HJ; Hayashi K; Salonga D; Danenberg KD; Danenberg PV; Metzger R; Banerjee D; Bertino JR; Groshen S; Leichman LP; Leichman CG
Clin Cancer Res; 1998 May; 4(5):1243-50. PubMed ID: 9607583
[TBL] [Abstract][Full Text] [Related]
7. TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival.
Børresen-Dale AL; Lothe RA; Meling GI; Hainaut P; Rognum TO; Skovlund E
Clin Cancer Res; 1998 Jan; 4(1):203-10. PubMed ID: 9516972
[TBL] [Abstract][Full Text] [Related]
8. Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression.
Kastrinakis WV; Ramchurren N; Rieger KM; Hess DT; Loda M; Steele G; Summerhayes IC
Oncogene; 1995 Aug; 11(4):647-52. PubMed ID: 7651727
[TBL] [Abstract][Full Text] [Related]
9. P53 mutations in colorectal cancer assessed in both genomic DNA and cDNA as compared to the presence of p53 LOH.
Forslund A; Kressner U; Lönnroth C; Andersson M; Lindmark G; Lundholm K
Int J Oncol; 2002 Aug; 21(2):409-15. PubMed ID: 12118339
[TBL] [Abstract][Full Text] [Related]
10. Humoral response to p53 is associated with conserved domains II and IV mutations in human colorectal cancer: a case-control study in Taiwan.
Wu CM; Tang R; Chen JR; Wu MC; Chien HT; Changchien CR; Hsieh LL
Oncol Rep; 2004 Nov; 12(5):1045-51. PubMed ID: 15492791
[TBL] [Abstract][Full Text] [Related]
11. Genotyping of p53 codon 175 in colorectal cancer.
Krajewska WM; Stawińska M; Bryś M; Młynarski W; Witas HW; Okruszek A; Kiliańska ZM
Med Sci Monit; 2003 May; 9(5):BR188-91. PubMed ID: 12761448
[TBL] [Abstract][Full Text] [Related]
12. Ki-ras codon 12 point and P53 mutations: a molecular examination of the main tumor, liver, portal vein, peripheral arterial blood and para-aortic lymph node in pancreatic cancer.
Yamaguchi K; Chijiiwa K; Torato N; Kinoshita M; Tanaka M
Am J Gastroenterol; 2000 Aug; 95(8):1939-45. PubMed ID: 10950039
[TBL] [Abstract][Full Text] [Related]
13. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
[TBL] [Abstract][Full Text] [Related]
14. Discordance of p53 mutations of synchronous colorectal carcinomas.
Eguchi K; Yao T; Konomoto T; Hayashi K; Fujishima M; Tsuneyoshi M
Mod Pathol; 2000 Feb; 13(2):131-9. PubMed ID: 10697269
[TBL] [Abstract][Full Text] [Related]
15. Molecular detection of neoplastic cells in lymph nodes of metastatic colorectal cancer patients predicts recurrence.
Sanchez-Cespedes M; Esteller M; Hibi K; Cope FO; Westra WH; Piantadosi S; Herman JG; Jen J; Sidransky D
Clin Cancer Res; 1999 Sep; 5(9):2450-4. PubMed ID: 10499618
[TBL] [Abstract][Full Text] [Related]
16. Characterization of p53 gene mutations in colorectal carcinomas from an Asian population.
Shi CY; Phang TW; Ngoi SS; Wee A; Li B; Lin Y; Lee HP; Ong CN
Anticancer Res; 1994; 14(6B):2811-6. PubMed ID: 7872723
[TBL] [Abstract][Full Text] [Related]
17. [p53 mutations and protein overexpression in primary colorectal cancer and its liver metastasis].
Yang Y; Xia Q; Lian F
Zhonghua Zhong Liu Za Zhi; 1999 Mar; 21(2):114-8. PubMed ID: 11776850
[TBL] [Abstract][Full Text] [Related]
18. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer.
Li YJ; Laurent-Puig P; Salmon RJ; Thomas G; Hamelin R
Oncogene; 1995 Feb; 10(3):599-601. PubMed ID: 7845685
[TBL] [Abstract][Full Text] [Related]
20. The role of combined allelic imbalance and mutations of p53 in tumor progression and survival following surgery for colorectal carcinoma.
Lagerstedt KK; Kressner U; Lönnroth C; Nordgren S; Lundholm K
Int J Oncol; 2005 Dec; 27(6):1707-15. PubMed ID: 16273227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
